As for Essence, the Medicare Advantage provider — which could have sent up its own flares beyond a paper mail notice when it ...

Ohio Senate President Rob McColley believes a "serious conversation" needs to be had on an immediate state property tax relief package, given that the lion's share of legislative action on ...

This consensual restructuring represents a landmark milestone for the company,” said Wes Edens, Chairman and CEO of New Fortress Energy. “’New NFE’ emerges from this transaction as a fundamentally ...

Mobix Labs, Inc. (Nasdaq: MOBX), a provider of advanced defense and aerospace technologies, today announced that it has been selected by a major munitions manufacturer to support a feasibility program ...

Perhaps the most crucial aspect is public awareness. Through mass media, social media, and local administration, extensive campaigns must be conducted to inform citizens of their rights, where to ...

Cycurion, Inc. (Nasdaq: CYCU) ('Cycurion” or the 'Company”), a trusted leader in IT cybersecurity solutions, today issued the following statement in response to an unauthorized press release dissemina ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ...

Nvidia is no longer removing stock-based compensation expenses from its adjusted earnings per share calculation.

Operation Guardian Trace,” as it’s called in a recently unearthed document, requires Immigration and Customs Enforcement to conduct in-person interviews with the relatives of undocumented children in ...

GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today ...

I am excited and honored to join Longeveron at this pivotal moment for the company. The strength of the company's stem cell science and success in multiple clinical trials across several indications ...